All In Biotech

Drug Trial Radar · NCT07943533

HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer

A Prospective, Exploratory Clinical Study to Evaluate the Efficacy and Safety of HLX22 in Combination With First-Line Therapy for HER2-Positive, Limited Metastatic, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Shanghai Zhongshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, exploratory study evaluating the efficacy and safety of HLX22 in combination with first-line systemic therapy in patients with HER2-positive, limited metastatic, unresectable gastric or gastroesophageal junction adenocarcinoma. Patients will receive HLX22 combined with trastuzumab and XELOX chemotherapy, with or without the PD-1 inhibitor HLX10 according to PD-L1 and mismatch repair status. The primary endpoint is objective response rate assessed by RECIST v1.1.

Conditions

  • HER2-Positive
  • Limited Metastatic
  • Gastric Cancer

Interventions

  • HLX22Drug

    HLX22 is administered intravenously every 3 weeks in combination with standard first-line systemic therapy, according to the protocol.

  • TrastuzumabDrug

    Trastuzumab is administered intravenously in combination with HLX22 and chemotherapy. A loading dose of 8 mg/kg is given at the first administration, followed by maintenance doses of 6 mg/kg every 3 weeks.

  • XELOX ChemotherapyDrug

    XELOX chemotherapy consists of:Oxaliplatin administered intravenously on Day 1 of each 3-week cycle;Capecitabine administered orally twice daily on Days 1-14 of each 3-week cycle.

  • HLX10Drug

    HLX10, a PD-1 inhibitor, is administered intravenously every 3 weeks in participants assigned to the CPS ≥5 or dMMR arm, according to the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: From the start of study treatment to the first tumor response assessment after 4 cycles (each cycle is 21 days; approximately 12 weeks), or up to 6 cycles (approximately 18 weeks) for participants receiving extended treatment.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.